Want to see AU:BIO full AI Analyst Report?
Top Page
Biome Australia Ltd
(Sydney:BIO)
Select Model
Select Model
Rating:56Neutral
Price Target:
AU$0.31
▲(18.85% Upside)
Action:Reiterated
Date:07/30/26
The score is driven primarily by moderate financial performance—strong revenue growth and a stable balance sheet are offset by weak cash conversion (negative operating cash flow) and thin profitability. Technically, the stock shows some near-term strength versus shorter moving averages but remains below the 200-day average, limiting the trend outlook. Valuation is a notable headwind due to the very high P/E.
Positive Factors
Revenue Growth
Sustained top-line expansion indicates growing market adoption of Biome's probiotic products and distribution reach. Durable revenue growth supports reinvestment in product development and marketing, helps absorb fixed costs, and underpins longer-term scale economics across channels.
Negative Factors
Operating Cash Flow Weakness
Negative operating cash flow despite reported growth points to weak cash conversion from core operations, likely from working capital or receivables. This structural cash shortfall limits self‑funding ability, increasing reliance on external financing for sustained growth or capex.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Sustained top-line expansion indicates growing market adoption of Biome's probiotic products and distribution reach. Durable revenue growth supports reinvestment in product development and marketing, helps absorb fixed costs, and underpins longer-term scale economics across channels.
Read all positive factors
Biome Australia Ltd (BIO) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$63.84M
Dividend YieldN/A
Average Volume (3M)278.69K
Price to Earnings (P/E)65.1
Beta (1Y)1.12
Revenue Growth38.44%
EPS Growth230.77%
CountryAU
Employees30
SectorConsumer Defensive
Sector Strength42
IndustryBiotechnology
Share Statistics
EPS (TTM)<0.01
Shares Outstanding227,998,030
10 Day Avg. Volume235,222
30 Day Avg. Volume278,692
Financial Highlights & Ratios
PEG Ratio-4.04
Price to Book (P/B)21.27
Price to Sales (P/S)5.40
P/FCF Ratio-34.81
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$0.75Price Target Upside188.46% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.03
Revenue Forecast (FY)AU$36.50M
Biome Australia Ltd Business Overview & Revenue Model
Company Description
Biome Australia Limited, founded in 2018 and headquartered in Cremorne, Australia, specializes in the development, commercialization, and global distribution of live biotherapeutic and complementary health products. The company's product line feat...
How the Company Makes Money
Biome Australia primarily makes money by selling its probiotic and microbiome-related health products. Revenue is generated from product sales into the market through distribution channels such as pharmacies, health practitioners and other retail/...
Biome Australia Ltd Financial Statement Overview
Summary
Income Statement
65
Positive
Balance Sheet
70
Positive
Cash Flow
50
Neutral
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 21.95M | 18.42M | 13.01M | 7.24M | 4.11M | 2.32M |
| Gross Profit | 13.28M | 11.26M | 7.91M | 4.06M | 2.38M | 1.07M |
| EBITDA | 765.13K | 143.57K | -1.58M | -3.15M | -4.65M | -5.39M |
| Net Income | 957.91K | 214.66K | -1.67M | -3.08M | -4.54M | -5.38M |
Balance Sheet | ||||||
| Total Assets | 12.31M | 11.97M | 8.28M | 7.56M | 8.25M | 11.09M |
| Cash, Cash Equivalents and Short-Term Investments | 3.36M | 2.75M | 2.87M | 2.26M | 5.49M | 634.61K |
| Total Debt | 2.43M | 3.07M | 1.30M | 1.15M | 467.05K | 81.00K |
| Total Liabilities | 6.25M | 7.29M | 5.37M | 3.97M | 1.73M | 920.00K |
| Stockholders Equity | 6.06M | 4.68M | 2.90M | 3.59M | 6.53M | 10.17M |
Cash Flow | ||||||
| Free Cash Flow | 355.74K | -2.86M | -185.41K | -3.90M | -3.55M | -2.46M |
| Operating Cash Flow | 390.84K | -2.82M | -163.81K | -3.50M | -3.42M | -2.39M |
| Investing Cash Flow | -140.48K | -200.38K | -21.61K | -400.94K | -99.34K | -28.77K |
| Financing Cash Flow | 518.57K | 2.90M | 793.17K | 665.21K | 8.40M | 2.58M |
Biome Australia Ltd Technical Analysis
Positive
0.26
Price Trends
0.27
Positive
0.29
Negative
0.36
Negative
Market Momentum
<0.01
Negative
54.44
Neutral
55.19
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:BIO, the sentiment is Positive. The current price of 0.26 is below the 20-day moving average (MA) of 0.27, below the 50-day MA of 0.27, and below the 200-day MA of 0.36, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 54.44 is Neutral, neither overbought nor oversold. The STOCH value of 55.19 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:BIO.
Biome Australia Ltd Peers Comparison
UnderperformOutperform
Sector (62)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
56 Neutral | AU$63.84M | 65.12 | 17.85% | ― | 38.44% | 230.77% | |
54 Neutral | AU$73.41M | -13.57 | -258.19% | ― | 9.28% | -40.00% | |
52 Neutral | AU$11.62M | -1.93 | -43.95% | ― | 14.30% | 41.93% | |
44 Neutral | AU$72.53M | -8.57 | -40.65% | ― | -100.00% | -11.11% | |
41 Neutral | AU$3.16M | -2.50 | -109.45% | ― | ― | 43.14% | |
41 Neutral | AU$113.04M | -3.27 | 279.21% | ― | ― | -37.23% |
* Consumer Defensive Sector Average
AU:BIO
Biome Australia Ltd
0.29
-0.24
-44.76%
AU:IMC
Immuron Limited
0.03
-0.04
-52.94%
AU:AVE
Avecho Biotechnology Limited
0.02
0.01
120.00%
AU:ANR
Anatara Lifesciences Ltd
0.01
0.00
0.00%
AU:RCE
Recce Pharmaceuticals Ltd.
0.38
0.00
0.00%
AU:ALA
Arovella Therapeutics Limited
0.06
-0.04
-41.90%
Biome Australia Ltd Corporate Events
Biome Australia posts record sales as Biome Daily tops probiotic market
Jul 28, 2026
Biome Australia has cemented its position in the microbiome health sector, reporting that Biome Daily is now the top-selling probiotic in Australian pharmacies by both units and value. The company’s Activated Probiotics and Activated Therape...
Biome Australia Sets FY27 Priorities After FY26 International Markets Review
Jul 27, 2026
Biome Australia has released an investor update reviewing its FY26 international market performance and outlining priorities for FY27, signalling a continued push into offshore markets and a focus on margin and manufacturing efficiency. The compan...
Biome Australia to brief investors on Q4 results and global expansion
Jul 26, 2026
Biome Australia Ltd will host an investor webinar on 3 August 2026 to discuss its Q4 FY26 quarterly results and a detailed update on international markets. The session, led by the founder and CFO, is designed to brief investors ahead of the releas...
Biome Australia Director Increases Equity Stake via On-Market Share Purchase
Jun 25, 2026
Biome Australia Limited has disclosed a change in director Blair Vega Norfolk’s interests, with Norfolk directly acquiring an additional 100,000 fully paid ordinary shares in an on-market purchase valued at about $25,030. Following this tran...
Biome Australia Director Increases Direct Shareholding via On-Market Purchase
Jun 3, 2026
Biome Australia director Blair Vega Norfolk has increased their direct holding in the company through an on-market purchase of 102,000 fully paid ordinary shares. The transaction, completed on 3 June 2026 for approximately $26,840, lifts Norfolk&#...
Biome Australia Highlights Growth and Profitability in H1 FY26 Update
Jun 2, 2026
Biome Australia reported its H1 FY26 results alongside a company presentation that underscores its status as Australia’s fastest-growing probiotic brand. The business highlights that it is clinically backed, profitable, and in a scaling phas...
Biome Australia to spotlight BMB18 clinical program and IP strategy in June investor webinar
May 26, 2026
Biome Australia will host a 30-minute investor webinar on 5 June 2026 to outline its intellectual property and research strategy, focusing on the BMB18 clinical program underway at La Trobe University in Melbourne and Harokopio University in Athen...
Biome Australia starts international multi-centre trial for first proprietary probiotic strain
May 26, 2026
Biome Australia has launched a multi-centre, randomised, double-blind, placebo-controlled clinical trial of its first proprietary probiotic strain, BMB18 (Lactiplantibacillus plantarum, DSM 35214), across La Trobe University in Melbourne and Harok...
Biome Australia extends exclusive Probiotical supply deal to 2028
May 11, 2026
Biome Australia has secured a two-year extension to its exclusive supply agreement with long-standing strain partner Probiotical SpA, pushing the deal’s expiry from June 2026 to 2028 on unchanged commercial terms. The renewed arrangement und...
Biome Australia Director Increases Indirect Shareholding via On-Market Purchase
Apr 30, 2026
Biome Australia Limited has disclosed a change in the indirect shareholding of director Geoffrey Sam, reflecting a routine update to his notifiable interest in the company. The notice shows that Sam, through family-related entities Burrangong Pty ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.